Lars Rebien Sørensen

Member of the Board since 2017 and Chair since July 2018.

Lars Rebien Sørensen was born in 1954 and is a Danish national. He received an MSc in Forestry from the Copenhagen Royal Veterinary and Agricultural University in 1981 and a BSc in International Economics from Copenhagen Business School in 1983.

Lars Rebien Sørensen has over 35 years of general management experience in the pharmaceutical industry. He joined the Novozymes A/S (then Novo Nordisk A/S, Enzymes Division) Marketing team in 1982. Over the years he held various global positions across the Middle East and the United States. In 1994, he was appointed a member of the corporate management team and assumed responsibility for the Novozymes A/S Healthcare Business. In November 2000, he became President and CEO of Novo Nordisk A/S, a position he held until December 2016.

Other Board Positions and Management Duties:

• Chair of the Board, Novo Nordisk Foundation, Denmark

• Executive Chair of the Board, Ferring Pharmaceuticals, Switzerland

• Chair of the Advisory Board, Axcel Management A/S, Denmark

• Board Member, Thermo Fischer Scientific Inc., United States

• Board Member, Essity AB, Sweden

• Board Member, Jungbunzlauer Suisse AG, Switzerland

• Adjunct Professor, the University of Copenhagen’s School of Life Sciences (appointed in 2007)

• Adjunct Professor, the Center for Corporate Governance at Copenhagen Business School (appointed in 2018)

Please contact the Chairman via   
Senior PA Trine Sewohl
+45 2065 5135
tse@novo.dk